UPB - NASDAQ

Upstream Bio, Inc.

UPB·NASDAQ

$20.97

-5.9%

HealthcareBiotechnology

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.13B

EPS-0.7400

P/E Ratio-3.69

Earnings Date11/06/2025

upb

Total Non-Current Assets

Last Annual Value

2.56M

3-Year CAGR

146%

5-Year CAGR

72%

10-Year CAGR

31%

Adjust for Inflation

Upstream Bio, Inc. Competitors Analysis of Total Non-Current Assets

UPB · NASDAQ

Company	Total Non-Current Assets	CAGR 3Y	CAGR 5Y	CAGR 10Y
Upstream Bio, Inc. NASDAQ:UPB	2.56M	133.1%	N/A	N/A
Dianthus Therapeutics, Inc. NASDAQ:DNTH	121.48M	296.2%	67.4%	72.9%
Praxis Precision Medicines, Inc. NASDAQ:PRAX	327.00M	374.1%	127.7%	N/A
Prime Medicine, Inc. NASDAQ:PRME	161.44M	46.9%	38.9%	N/A
Relay Therapeutics, Inc. NASDAQ:RLAY	43.05M	-16.5%	6.0%	N/A
Septerna, Inc. NASDAQ:SEPN	185.22M	116.8%	N/A	N/A
Zenas BioPharma, Inc. NASDAQ:ZBIO	32.47M	57.1%	N/A	N/A
Bicara Therapeutics Inc. Common Stock NASDAQ:BCAX	8.94M	45.4%	N/A	N/A
Nektar Therapeutics NASDAQ:NKTR	14.14M	-40.6%	-46.5%	-20.6%
Phathom Pharmaceuticals, Inc. NASDAQ:PHAT	30.18M	22.5%	59.7%	N/A

Upstream Bio, Inc. Fair Value Envelope

UPB · NASDAQ

Our analysis suggests that UPB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $20.97, this represents a potential HIDDEN relative to our calculated worth for Upstream Bio, Inc..

HIDDEN

Intrinsic Value

Current Price: $20.97

Related Guides

Blog Categories

Continue your UPB research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.